Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese PLA General Hospital
• Collaborator: Roche Pharma AG
• Treatments: Bevacizumab; Cisplatin

Criteria

Inclusion Criteria:

• Patients with advanced recurrent or progressive NSCLC proven cytohistologically

• Karnofsky performance status (KPS) ≥60

• Life expectancy ≥ 2 months

• No history of severe diseases of major organs including liver, heart, and kidney

• No previous intrapleural therapy

• Written informed consent

Exclusion Criteria:

• Active thoracic cavity or systemic bleeding

• Active pleural or systemic infection.

• Known sensitivity to Bevacizumab or Cisplatin

• Refusal to participate in the study.